Tariquidar
Tariquidar is a potent P-glycoprotein inhibitor and a substrate of breast cancer protein undergoing research as an adjuvant against multi-drug resistance in cancer.
Tariquidar progressed to phase III clinical trials in combination with vinorelbine in an effort to enhance the efficacy of this chemotherapeutic agent. However, several of these trials were terminated early due to adverse effects, and further development of Tariquidar was subsequently halted.